Charles S. Berkman Sells 8,215 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 8,215 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total value of $30,231.20. Following the completion of the sale, the insider now owns 364,131 shares in the company, valued at $1,340,002.08. This represents a 2.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

OmniAb Price Performance

NASDAQ OABI traded up $0.01 during mid-day trading on Wednesday, hitting $3.67. The company’s stock had a trading volume of 294,723 shares, compared to its average volume of 489,354. The firm has a market capitalization of $518.28 million, a P/E ratio of -5.92 and a beta of -0.12. OmniAb, Inc. has a 52-week low of $3.10 and a 52-week high of $6.55. The stock’s fifty day simple moving average is $3.49 and its two-hundred day simple moving average is $3.91.

Hedge Funds Weigh In On OmniAb

Hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC boosted its position in OmniAb by 33.3% during the 4th quarter. Squarepoint Ops LLC now owns 39,264 shares of the company’s stock worth $139,000 after purchasing an additional 9,809 shares during the period. Sherbrooke Park Advisers LLC lifted its stake in shares of OmniAb by 53.5% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company’s stock worth $61,000 after purchasing an additional 6,001 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of OmniAb by 29.9% in the fourth quarter. ProShare Advisors LLC now owns 31,724 shares of the company’s stock worth $112,000 after buying an additional 7,302 shares during the period. Northeast Financial Consultants Inc acquired a new stake in shares of OmniAb in the fourth quarter valued at about $393,000. Finally, Millennium Management LLC raised its holdings in shares of OmniAb by 49.7% during the 4th quarter. Millennium Management LLC now owns 186,745 shares of the company’s stock valued at $661,000 after buying an additional 61,993 shares during the period. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on OABI. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reaffirmed a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.